EGFR and breast carcinoma: While the loss or reduced expression of nuclear BRCA1 is prevalent in basal-like breast cancers with negative estrogen, progesterone, and epidermal growth factor receptors (triple negative), its cytosolic expression is observed in estrogen-positive receptor breast cancers (68).